Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. The company is headquartered in Bedminster, New Jersey and currently employs 860 full-time employees. The firm leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.

Industry: Pharmaceutical Preparations Peers: Catalent, Inc. CORCEPT THERAPEUTICS INC Elanco Animal Health Inc Harmony Biosciences Holdings Inc Johnson & Johnson Organon & Co Prestige Consumer Healthcare Inc Royalty Pharma PLC Viatris Inc